RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Deciphera Pharmaceuticals Stock

Deciphera Pharmaceuticals Revenue 2024

Deciphera Pharmaceuticals Revenue

205.66 M USD

Ticker

DCPH

ISIN

US24344T1016

WKN

A2H48H

In 2024, Deciphera Pharmaceuticals's sales reached 205.66 M USD, a 25.9% difference from the 163.36 M USD sales recorded in the previous year.

The Deciphera Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e610.8826,13
2028e509.3331,34
2027e434.3136,75
2026e382.4641,74
2025e264.660,33
2024e205.6677,62
2023163.3697,72
2022134.0493,46
202196.1596,95
202042.0999,47
201925638,50
2018--
2017--
2016--
2015--

Deciphera Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Deciphera Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Deciphera Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Deciphera Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Deciphera Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Deciphera Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Deciphera Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Deciphera Pharmaceuticals’s growth potential.

Deciphera Pharmaceuticals Revenue, EBIT and net profit per share

DateDeciphera Pharmaceuticals RevenueDeciphera Pharmaceuticals EBITDeciphera Pharmaceuticals Net Income
2029e610.88 M undefined0 undefined136.72 M undefined
2028e509.33 M undefined53.93 M undefined61.09 M undefined
2027e434.31 M undefined-25.1 M undefined-38.59 M undefined
2026e382.46 M undefined-73.21 M undefined-50.66 M undefined
2025e264.6 M undefined-168.31 M undefined-137.12 M undefined
2024e205.66 M undefined-203.21 M undefined-187.97 M undefined
2023163.36 M undefined-210.96 M undefined-194.94 M undefined
2022134.04 M undefined-182.72 M undefined-178.93 M undefined
202196.15 M undefined-300.08 M undefined-299.96 M undefined
202042.09 M undefined-271.19 M undefined-266.49 M undefined
201925 M undefined-200.73 M undefined-192.26 M undefined
20180 undefined-104.1 M undefined-99.85 M undefined
20170 undefined-50.94 M undefined-50.28 M undefined
20160 undefined-25.84 M undefined-25.94 M undefined
20150 undefined-17.61 M undefined-19.82 M undefined

Deciphera Pharmaceuticals stock margins

The Deciphera Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Deciphera Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Deciphera Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Deciphera Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Deciphera Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Deciphera Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Deciphera Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Deciphera Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Deciphera Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Deciphera Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Deciphera Pharmaceuticals Margin History

Deciphera Pharmaceuticals Gross marginDeciphera Pharmaceuticals Profit marginDeciphera Pharmaceuticals EBIT marginDeciphera Pharmaceuticals Profit margin
2029e97.72 %0 %22.38 %
2028e97.72 %10.59 %11.99 %
2027e97.72 %-5.78 %-8.89 %
2026e97.72 %-19.14 %-13.25 %
2025e97.72 %-63.61 %-51.82 %
2024e97.72 %-98.81 %-91.4 %
202397.72 %-129.14 %-119.34 %
202293.46 %-136.32 %-133.49 %
202196.95 %-312.1 %-311.98 %
202099.47 %-644.36 %-633.19 %
201997.72 %-802.9 %-769.02 %
201897.72 %0 %0 %
201797.72 %0 %0 %
201697.72 %0 %0 %
201597.72 %0 %0 %

Deciphera Pharmaceuticals Aktienanalyse

What does Deciphera Pharmaceuticals do?

Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Deciphera Pharmaceuticals's Sales Figures

The sales figures of Deciphera Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Deciphera Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Deciphera Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Deciphera Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

How much revenue did Deciphera Pharmaceuticals generate this year?

Deciphera Pharmaceuticals has achieved a revenue of 205.66 M USD this year.

How much was the turnover of the company Deciphera Pharmaceuticals compared to the previous year?

The revenue of Deciphera Pharmaceuticals has increased by 25.9% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Deciphera Pharmaceuticals?

The revenue of Deciphera Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Deciphera Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Deciphera Pharmaceuticals so important for investors?

The revenue of Deciphera Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Deciphera Pharmaceuticals pay?

Over the past 12 months, Deciphera Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Deciphera Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Deciphera Pharmaceuticals?

The current dividend yield of Deciphera Pharmaceuticals is .

When does Deciphera Pharmaceuticals pay dividends?

Deciphera Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Deciphera Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Deciphera Pharmaceuticals located?

Deciphera Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Deciphera Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Deciphera Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Deciphera Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Deciphera Pharmaceuticals in the year 2023?

In the year 2023, Deciphera Pharmaceuticals distributed 0 USD as dividends.

In which currency does Deciphera Pharmaceuticals pay out the dividend?

The dividends of Deciphera Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Deciphera Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Deciphera Pharmaceuticals

Our stock analysis for Deciphera Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.